MENLO PARK, Calif., Oct. 24, 2013 /PRNewswire/ -- Telomere Diagnostics, Inc. (TDx), developer of the TeloTest™ diagnostic test that measures average telomere length in human cells from a saliva sample, announces that it has changed its corporate name from Telome Health, Inc. to Telomere Diagnostics Inc. (www.telomereDx.com) This name change comes as a confirmation of the long-term strategy of the company, which is to become the global market leader in telomere-related testing for the prevention, diagnosis and management of human diseases and premature aging.
After the CLIA certification of its lab in early 2013, Telomere Diagnostics (previously known as Telome Health) has initiated a controlled launch of the Telotest™ among a small selection of physicians. It is planning to make the Telotest™ fully available to physicians in the U.S. for the wellness market in the coming months. In addition, TDx is validating additional and complementary diagnostic tests focused on Telomere Biology, in order to increase the predictive power of its existing panel.
"As we are planning to fully launch our Telotest™ in the Wellness market, this name change comes as a confirmation of our long-term commitment, which is to lead the way in the development of innovative assays based on Telomere Biology," explained TDx's interim CEO, Alexandre Le Vert. "We are working hard to complement this test with additional Telomere Biology based tests, so that we build a portfolio of strong prognostic and companion diagnostic tests going forward."
"We will leverage on our first diagnostic test, the Telotest™, to expand and build what we believe will be the most comprehensive panel of clinically and scientifically validated assays in Telomere Biology," stated TDx's Chief Scientific Officer, Calvin Harley, Ph.D
|SOURCE Telomere Diagnostics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved